IRADIMED CORP (IRMD) Stock Fundamental Analysis
USA - NASDAQ:IRMD - US46266A1097 - Common Stock
84.33 USD
-0.29 (-0.34%)
84.33 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to IRMD. IRMD was compared to 189 industry peers in the Health Care Equipment & Supplies industry. IRMD gets an excellent profitability rating and is at the same time showing great financial health properties. IRMD has a correct valuation and a medium growth rate. These ratings could make IRMD a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
In the past year IRMD had a positive cash flow from operations.
In the past 5 years IRMD has always been profitable.
IRMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IRMD's Return On Assets of 19.41% is amongst the best of the industry. IRMD outperforms 97.88% of its industry peers.
Looking at the Return On Equity, with a value of 21.91%, IRMD belongs to the top of the industry, outperforming 93.65% of the companies in the same industry.
IRMD has a Return On Invested Capital of 19.30%. This is amongst the best in the industry. IRMD outperforms 97.35% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 9.12%.
The last Return On Invested Capital (19.30%) for IRMD is above the 3 year average (18.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
IRMD has a better Profit Margin (26.61%) than 94.71% of its industry peers.
IRMD's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 30.67%, IRMD belongs to the top of the industry, outperforming 97.35% of the companies in the same industry.
In the last couple of years the Operating Margin of IRMD has grown nicely.
Looking at the Gross Margin, with a value of 76.96%, IRMD belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, IRMD has more shares outstanding
The number of shares outstanding for IRMD has been increased compared to 5 years ago.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 56.24 indicates that IRMD is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 56.24, IRMD belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 56.24 |
ROIC/WACC2.21
WACC8.75%
2.3 Liquidity
IRMD has a Current Ratio of 8.78. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
IRMD has a Current ratio of 8.78. This is amongst the best in the industry. IRMD outperforms 91.01% of its industry peers.
IRMD has a Quick Ratio of 7.51. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.51, IRMD belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 |
3. Growth
3.1 Past
IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.75%, which is quite good.
The Earnings Per Share has been growing by 13.92% on average over the past years. This is quite good.
Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 11.71% in the last year.
IRMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.71% yearly.
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
Revenue 1Y (TTM)11.71%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.68%
3.2 Future
IRMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.26% yearly.
The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 46.34, which means the current valuation is very expensive for IRMD.
Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than 68.78% of the companies in the same industry.
IRMD is valuated expensively when we compare the Price/Earnings ratio to 25.67, which is the current average of the S&P500 Index.
IRMD is valuated quite expensively with a Price/Forward Earnings ratio of 39.46.
IRMD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 71.43% of the companies in the same industry.
IRMD is valuated rather expensively when we compare the Price/Forward Earnings ratio to 31.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.34 | ||
| Fwd PE | 39.46 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 68.25% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 70.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 80.46 | ||
| EV/EBITDA | 41.6 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)3.7
PEG (5Y)3.33
EPS Next 2Y13.8%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
IRMD has a yearly dividend return of 0.80%, which is pretty low.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.89. IRMD pays more dividend than 91.53% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
39.33% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.33%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
84.33
-0.29 (-0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners59.43%
Inst Owner Change-2.19%
Ins Owners36.81%
Ins Owner Change1.03%
Market Cap1.07B
Revenue(TTM)73.24M
Net Income(TTM)20.66M
Analysts82.5
Price Target76.5 (-9.28%)
Short Float %1.99%
Short Ratio3.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.33%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.43%
Min EPS beat(2)0.43%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)4.6%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)6.12%
EPS beat(12)10
Avg EPS beat(12)7.27%
EPS beat(16)14
Avg EPS beat(16)11.73%
Revenue beat(2)1
Avg Revenue beat(2)-0.52%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)0.01%
Revenue beat(8)3
Avg Revenue beat(8)-0.43%
Revenue beat(12)5
Avg Revenue beat(12)-0.16%
Revenue beat(16)7
Avg Revenue beat(16)-0.07%
PT rev (1m)2.04%
PT rev (3m)5.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.75%
EPS NY rev (1m)-0.54%
EPS NY rev (3m)6.05%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)3.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.34 | ||
| Fwd PE | 39.46 | ||
| P/S | 13.82 | ||
| P/FCF | 80.46 | ||
| P/OCF | 39.52 | ||
| P/B | 11.37 | ||
| P/tB | 11.8 | ||
| EV/EBITDA | 41.6 |
EPS(TTM)1.82
EY2.16%
EPS(NY)2.14
Fwd EY2.53%
FCF(TTM)1.05
FCFY1.24%
OCF(TTM)2.13
OCFY2.53%
SpS6.1
BVpS7.41
TBVpS7.15
PEG (NY)3.7
PEG (5Y)3.33
Graham Number17.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROCE | 24.39% | ||
| ROIC | 19.3% | ||
| ROICexc | 42.22% | ||
| ROICexgc | 45.68% | ||
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% | ||
| FCFM | 17.17% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexgc growth 3Y-6.9%
ROICexgc growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1738.97% | ||
| Cap/Sales | 17.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 110.32% | ||
| Profit Quality | 64.54% | ||
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 | ||
| Altman-Z | 56.24 |
F-Score4
WACC8.75%
ROIC/WACC2.21
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue 1Y (TTM)11.71%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.68%
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
EBIT growth 1Y11.02%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.2%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y79.39%
OCF growth 3Y31.53%
OCF growth 5Y20.16%
IRADIMED CORP / IRMD FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 7 / 10 to IRMD.
What is the valuation status of IRADIMED CORP (IRMD) stock?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
Can you provide the profitability details for IRADIMED CORP?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
How financially healthy is IRADIMED CORP?
The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.
Is the dividend of IRADIMED CORP sustainable?
The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 39.33%.